Sort

Search

Search Bar
01/12/2025 Update 2025 of the Spanish COPD Guidelines (GesEPOC): Pharmacological Treatment of Stable COPD
Miravitlles, M, Calle, M, Molina, J, Almagro, P, Gomez, JT, Trigueros, JA, Sánchez-Angarita, E, Cosio, BG, Casanova, C, López-Campos, JL, Riesco, JA, Simonet, P, Rigau, D, Iskakova, A, Sanz, MP, Sobradillo, P, Alcázar-Navarrete, B, Garin, N, Soler-Cataluña, JJ. Update 2025 of the Spanish COPD Guidelines (GesEPOC): Pharmacological Treatment of Stable COPD. ARCHIVOS DE BRONCONEUMOLOGIA. 2025; 61(12)DOI:10.1016/j.arbres.2025.10.008. PMID:41198528. IF:9.200(Q1/1D).
01/12/2025 Aligning research funding and the production of useful evidence to reduce research waste
Meza, N, Madrid, E, Urrútia, G, Clarke, M. Aligning research funding and the production of useful evidence to reduce research waste. Bmj Evidence-Based Medicine. 2025; 30(6)DOI:10.1136/bmjebm-2025-114324. PMID:41326283. IF:7.600(Q1/1D).
01/12/2025 ADOLESBIO-HS: A Real-World Multicenter Case Series on the Effectiveness and Safety of Adalimumab in Adolescents with Moderate-to-Severe Hidradenitis Suppurativa
Grau-Pérez, M, Ciudad, C, Molina-Leyva, A, Martorell, A, Vilarrasa, E, Albert, I, Garcias-Ladaria, J, Melgosa, FJ, Rivera, R, Campos, M, Haselgruber, S, Ochando, G, Pascual, JC, García-Ruiz, R, Alfageme, F. ADOLESBIO-HS: A Real-World Multicenter Case Series on the Effectiveness and Safety of Adalimumab in Adolescents with Moderate-to-Severe Hidradenitis Suppurativa. DERMATOLOGY. 2025; 241(5-6)DOI:10.1159/000546647. PMID:40587963. IF:2.700(Q2/4D).
01/12/2025 REVIEW OF PATIENT DECISION AIDS FOR PSORIASIS
Ferrer, AL, Belinchón, I, Serra, MC, Clua, MG, Mate, AR, Suárez, BP, Alarcón, SS, de la Cueva, P. REVIEW OF PATIENT DECISION AIDS FOR PSORIASIS. VALUE IN HEALTH. 2025; 28(12)DOI:. PMID:. IF:6.000(Q1/1D).
01/12/2025 UNDERSTANDING PATIENT PRIORITIES IN PSORIASIS TREATMENT: A REVIEW OF KEY DECISION-MAKING DRIVERS
Ferrer, AL, Belinchón, I, Serra, MC, Martínez, LE, Mate, AR, Suárez, BP, Alarcón, SS, de la Cueva, P. UNDERSTANDING PATIENT PRIORITIES IN PSORIASIS TREATMENT: A REVIEW OF KEY DECISION-MAKING DRIVERS. VALUE IN HEALTH. 2025; 28(12)DOI:. PMID:. IF:6.000(Q1/1D).
01/12/2025 HIGHER MORTALITY FOR GENERALIZED PUSTULAR PSORIASIS COMPARED WITH PLAQUE PSORIASIS HIGHLIGHTS THE NEED FOR IMPROVED TREATMENTS: INSIGHTS FROM A META-ANALYSIS
Strober, B, Puig, L, Lebwohl, MG, Lakshminarasimhan, B, Khan, SA, Pillai, N, Kappelhoff, B, Weatherill, A, Warren, RB. HIGHER MORTALITY FOR GENERALIZED PUSTULAR PSORIASIS COMPARED WITH PLAQUE PSORIASIS HIGHLIGHTS THE NEED FOR IMPROVED TREATMENTS: INSIGHTS FROM A META-ANALYSIS. VALUE IN HEALTH. 2025; 28(12)DOI:. PMID:. IF:6.000(Q1/1D).
01/12/2025 Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group
Li, R, Hensley, PJ, Babjuk, M, Bukavina, L, Psutka, SP, Lerner, SP, O'Donnell, MA, Lotan, Y, Bree, KK, Redorta, JP, McConkey, DJ, Lee, BH, Mariappan, P, Mertens, LS, Soloway, MS, Svatek, RS, Tan, WS, Williams, SB, Gupta, S, Buckley, R, Kamat, AM. Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group. European Urology Oncology. 2025; 8(6)DOI:10.1016/j.euo.2025.08.003. PMID:41076366. IF:9.300(Q1/1D).
01/12/2025 Twenty-year Patient-reported Outcomes After Surgery, Radiotherapy, or Brachytherapy for Localized Prostate Cancer
Zamora, V, Garin, O, Suárez, JF, Guedea, F, Pont, A, Pardo, Y, Goñi, A, Mariño, A, Hervás, A, Herruzo, I, Cabrera, P, Sancho, G, León, JPD, Macías, V, Gutiérrez, C, Castells, M, Ferrer, M. Twenty-year Patient-reported Outcomes After Surgery, Radiotherapy, or Brachytherapy for Localized Prostate Cancer. European Urology Open Science. 2025; 82DOI:10.1016/j.euros.2025.10.007. PMID:41311640. IF:4.500(Q1/2D).